This proposal, Clinical and Molecular Studies of Malignant Brain Tumors, builds upon my decade-long experience conducting highly productive patient-oriented research and successful mentoring of 26 neuro-oncology fellows at the Massachusetts General Hospital Cancer Center. The focus of the research strategy proposed in this application is to develop improved diagnostic and therapeutic approaches for malignant brain tumors. The protected time afforded to me during the first 5 years of this K24 award enabled me to complete multiple patient-oriented research projects, publish more than 95 papers, successfully compete for 3 peer-reviewed NIH and 2 foundation research grants as principal investigator, and mentor 11 current and past fellows and junior faculty members. Renewal of the award will enable me to expand my mentoring role to other oncology-related disciplines and to conduct patient-oriented research projects across new areas of neuro-oncology including brain metastases. Resources that will enable this expansion and assure success of a second 5-year period of funding include a neuro-oncology patient volume base that has doubled over the last 5 years, clinical trial accrual that has quadrupled over the last 5 years and a growing fellow and junior faculty group of investigators that provides an outstanding pool of potential mentees. In light of the expanding clinical volume it is imperative that I retain the ability to protect my time for patient-oriented research and mentoring. The expansion of my patient-oriented research and mentoring to other oncology-related disciplines will also enable me to secure additional peer-reviewed grant funding in new areas not currently represented in my active grant portfolio, which will further expand opportunities for future mentees. The award will enable me to further enhance my career as a patient-oriented researcher as well as my ability to mentor young investigators from neuro-oncology, medical oncology, neuroradiology/cancer imaging, transplant oncology and related disciplines.

Public Health Relevance

The award, Clinical and Molecular Studies of Malignant Brain Tumors, will enable new avenues of research into brain tumors and will expand the pool of young clinician-investigators who choose research careers dedicated to the study of these devastating types of human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
2K24CA125440-06
Application #
8383410
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
2007-08-01
Project End
2017-07-31
Budget Start
2012-08-03
Budget End
2013-07-31
Support Year
6
Fiscal Year
2012
Total Cost
$185,972
Indirect Cost
$13,776
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Arrillaga-Romany, Isabel; Chi, Andrew S; Allen, Joshua E et al. (2017) A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 8:79298-79304
Ellingson, Benjamin M; Gerstner, Elizabeth R; Smits, Marion et al. (2017) Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res 23:5745-5756
Andronesi, Ovidiu C; Esmaeili, Morteza; Borra, Ronald J H et al. (2017) Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol 1:
Han, Catherine H; Batchelor, Tracy T (2017) Primary Central Nervous System Lymphoma. Continuum (Minneap Minn) 23:1601-1618
Yáñez, M Loreto; Miller, Julie J; Batchelor, Tracy T (2017) Diagnosis and treatment of epidural metastases. Cancer 123:1106-1114
Tateishi, Kensuke; Higuchi, Fumi; Miller, Julie J et al. (2017) The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res 77:4102-4115
Wang, Nancy; Jain, Rakesh K; Batchelor, Tracy T (2017) New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics 14:321-332
Tateishi, Kensuke; Iafrate, A John; Ho, Quan et al. (2016) Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res 22:4452-65
Peterson, Teresa E; Kirkpatrick, Nathaniel D; Huang, Yuhui et al. (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 113:4470-5
Andronesi, Ovidiu C; Loebel, Franziska; Bogner, Wolfgang et al. (2016) Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res 22:1632-41

Showing the most recent 10 out of 62 publications